Research programme: G-protein coupled receptor modulators - TrevenaAlternative Names: TRV 250
Latest Information Update: 01 Apr 2015
At a glance
- Originator Trevena
- Class Small molecules
- Mechanism of Action G protein-coupled receptor modulators; Opioid delta receptor modulators; Opioid kappa receptor modulators; Opioid mu receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Major depressive disorder; Migraine; Pain; Parkinson's disease
- No development reported Cachexia; Inflammation